Subscribe to RSS
DOI: 10.1055/s-2006-925165
Low Frequency of Colorectal Dysplasia in Patients with Long-Standing Inflammatory Bowel Disease Colitis: Detection by Fluorescence Endoscopy
Publication History
Submitted 2 September 2004
Accepted after revision 5 September 2005
Publication Date:
09 May 2006 (online)
Background and Study Aim: Patients with long-standing inflammatory bowel disease (IBD) have an increased risk of developing colonic dysplasias. Dysplastic changes in flat mucosa are likely to be missed by conventional colonoscopy. Endoscopic fluorescence imaging, using 5-aminolevulinic acid (5-ALA) as photosensitizer, has evolved as a new technique to differentiate between normal colonic mucosa and dysplasia. We combined this technique with random biopsies to prospectively evaluate the occurrence of dysplasias in patients with long-standing IBD.
Patients and Methods: 52 colonoscopies were performed in 42 consecutive patients (n = 28 with ulcerative colitis, n = 11 with Crohn’s colitis, n = 3 with indeterminate colitis; mean age 43 years, range 21 - 78) with long-standing IBD colitis (median disease duration 14 years, range 3 - 40). All patients were in clinical remission. Patients were examined using both conventional white light and by fluorescence colonoscopy using oral 5-ALA. Four biopsies were taken every 10 cm from mucosa of normal appearance. In addition, macroscopically suspicious and fluorescence-positive areas were biopsied.
Results: A total of 688 biopsies of red-fluorescent (n = 20) and nonfluorescent (n = 662) areas of mucosa were taken. Dysplasia was detected histopathologically in only two of the biopsies. These biopsies were taken from two polypoid lesions which were fluorescence-negative.
Conclusions: The rate of colonic dysplasia in patients with long-standing IBD colitis may be lower than previously reported.
References
- 1 Farrell R J, Peppercorn M A. Ulcerative colitis. Lancet. 2002; 359 331-340
- 2 Rutter M, Saunders B, Wilkinson K. et al . Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004; 126 451-459
- 3 Greenstein A J, Sachar D B, Smith H. et al . A comparison of cancer risk in Crohn’s disease and ulcerative colitis. Cancer. 1981; 48 2742-2745
- 4 Weedon D D, Shorter R G, Ilstrup D M. et al . Crohn’s disease and cancer. N Engl J Med. 1973; 289 1099-1103
- 5 Gyde S N, Prior P, Macartney J C. et al . Malignancy in Crohn’s disease. Gut. 1980; 21 1024-1029
- 6 Ekbom A, Helmick C, Zack M, Adami H-O. Increased risk of large bowel cancer in Crohn’s disease with colonic involvement. Lancet. 1990; 336 357-359
- 7 Bernstein C N, Blanchard J F, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001; 91 854-862
- 8 Rhodes J M, Campbell B J. Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends Mol Med. 2002; 8 10-16
- 9 Ullman T A, Loftus Jr E V , Kakar S. et al . The fate of low grade dysplasia in ulcerative colitis. Am J Gastroenterol. 2002; 97 922-927
- 10 Ransohoff D F, Riddell R H, Levin B. Ulcerative colitis and colonic cancer. Problems in assessing the diagnostic usefulness of mucosal dysplasia. Dis Colon Rectum. 1985; 28 383-388
- 11 Raithel M, Weidenhiller M, Schwab D. et al . Pathobiology of dysplasia in chronic inflammatory bowel disease: Current recommendations for surveillance of dysplasia [in German]. Z Gastroenterol. 2001; 39 861-875
- 12 Messmann H. Fluorescence endoscopy in gastroenterology. Z Gastroenterol. 2000; 38 21-30
- 13 Stepp H, Sroka R, Baumgartner R. Fluorescence endoscopy of gastrointestinal diseases: basic principles, techniques and clinical experience. Endoscopy. 1998; 30 379-386
- 14 Sackmann M. Fluorescence diagnosis in GI endoscopy. endoscopy. 2000; 32 1-9
- 15 Messmann H, Endlicher E, Freunek G. et al . Fluorescence endoscopy for the detection of low and high grade dysplasia in ulcerative colitis using systemic or local 5-aminolaevulinic acid sensitisation. Gut. 2003; 52 1003-1007
- 16 Messmann H, Knüchel R, Bäumler W. et al . Endoscopic fluorescence detection of dysplasia in patients with Barrett’s esophagus, ulcerative colitis, or adenomatous polyps after 5-aminolevulinic acid-induced protoporphyrin IX sensitization. Gastrointest Endosc. 1999; 49 97-101
- 17 Messmann H, Kullmann F, Wild T. et al . Detection of dysplastic lesions by fluorescence in a model of colitis in rats after previous photosensitization with 5-aminolaevulinic acid. Endoscopy. 1998; 30 333-338
- 18 Best W R, Becktel J M, Singleton J W, Kern Jr F . Development of a Crohn’s disease activity index. Gastroenterology. 1976; 70 439-444
- 19 Lichtiger S, Present D H, Kornbluth A. et al . Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994; 330 1841-1845
- 20 Shetty K, Rybicki L, Brzezinski A. et al . The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol.. 1999; 94 1643-1649
- 21 Kornfeld D, Ekbom A, Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut. 1997; 41 522-525
- 22 Marchesa P, Lashner B A, Lavery I C. et al . The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. Am J Gastroenterol.. 1997; 92 1285-1288
- 23 Batlle A M. Porphyrins, porphyrias, cancer and photodynamic therapy - a model for carcinogenesis. J Photochem Photobiol B. 1993; 20 5-22
- 24 Kennedy J C, Pottier R H. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B. 1992; 14 275-292
- 25 Peng Q, Warloe T, Berg K. et al . 5-Aminolevulinic acid-based photodynamic therapy. Cancer. 1997; 79 2282-2308
- 26 Kiesslich R, Fritsch J, Holtmann M. et al . Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology. 2003; 124 880-888
- 27 Winther K V, Vruun E, Horn T. et al . Screening for dysplasia in patients with 22 - 40 years of ulcerative colitis in a population-based cohort from Copenhagen County. Gastroenterology. 2003; 124 (Suppl) A216
- 28 Rutter M D, Saunders B P, Schofield G, Forbes A, Price A B, Talbot I C. Pancolonic indigo carmine dye spraying for the detection of dysplasia in ulcerative colitis. Gut. 2004; 53 256-260
- 29 Peppercorn M A, Odze R D. Colorectal cancer surveillance in inflammatory bowel disease. UpToDate. 2006.; http://www.uptodate.com
- 30 Arnott I D, Drummond H E, Ghosh S. Frequency of continuing mucosal inflammation in clinically inactive Crohn’s disease. Scott Med J. 2001; 46 136-139
- 31 Beattie R M, Nicholls S W, Domizio P. et al . Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis. J Pediatr Gastroenterol Nutr. 1996; 22 373-379
-
32 Riddell R H.
Pathology of idiopathic inflammatory bowel disease. In: Kirsner JB (ed) Inflammatory bowel disease. 5th edn. Philadelphia; Saunders 2000: 427-448 - 33 Connell W R, Lennard-Jones J E, Williams C B. et al . Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology. 1994; 107 934-944
- 34 Melville D M, Jass J R, Shepherd N A. et al . Dysplasia and deoxyribonucleic acid aneuploidy in the assessment of precancerous changes in chronic ulcerative colitis. Observer variation and correlations. Gastroenterology. 1988; 95 668
- 35 Dixon M F, Brown L J, Gilmour H M. et al . Observer variation in the assessment of dysplasia in ulcerative colitis. Histopathology. 1988; 13 385
- 36 Lewis J D. The many faces of low-grade dysplasia. Gastroenterology. 2003; 125 1531-1533
- 37 van Hogezand R A, Eichhorn R F, Choudry A. et al . Malignancies in inflammatory bowel disease: fact or fiction?. Scand J Gastroenterol. 2002; 236 (Suppl) 48-53
- 38 Fraser A G, Orchard T R, Robinson E M, Jewell D P. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther. 2002; 16 1225-1232
- 39 Lynch D A, Lobo A J, Sobala G M. et al . Failure of colonoscopic surveillance in ulcerative colitis. Gut. 1993; 34 1075-1080
- 40 Albert M B, Nochomovitz L E. Dysplasia and cancer surveillance in inflammatory bowel disease. Gastroenterol Clin N Am. 1989; 18 83-97
- 41 Axon A T. Cancer surveillance in ulcerative colitis: a time for reappraisal. Gut. 1994; 35 587
- 42 Ullman T, Croog V, Harpaz N. et al . Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology. 2003; 125 1311-1319
- 43 Bernstein C N, Eaden J, Steinhart A H. et al . Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid. Inflamm Bowel Dis. 2002; 8 356-361
- 44 Mir-Madjlessi S H, Farmer R G, Easley K A, Beck G J. Colorectal and extracolonic malignancy in ulcerative colitis. Cancer. 1986; 58 1569-1574
- 45 Langholz E, Munkholm P, Davidsen M, Binder V. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology. 1992; 103 1444-1451
- 46 Brand S, Wang T D, Schomacker K T. et al . Detection of high-grade dysplasia in Barrett’s esophagus by spectroscopy measurement of 5-aminolevulinic acid-induced protoporphyrin IX fluorescence. Gastrointest Endosc. 2002; 56 479-487
Thomas Ochsenkühn, M. D.
Department of Medicine II
University of Munich-Grosshadern · Marchioninistrasse 15 · 81 366 Munich · Germany
Fax: +49-89 70955291·
Email: thomas.ochsenkuehn@med.uni-muenchen.de